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NOTES AND COMMENTS

Rubella: Current Status of Immunization
E. L . Quinn, M.D., Frank Cox, M . D . and Donald Romig, M . D . *

The chief cause of concern with
rubella—German measles—is its effect
on the fetus when the virus infects a
pregnant woman. An estimated 247,000 women in their first trimester of
pregnancy contracted rubella in the
1963-64 epidemic.^ The results: 8,000
to 30,000 fetal deaths and approximately 20,000 children born with congenital anomalies which included deafness, eye defects, mental retardation
and heart lesions.
Since epidemics of rubella occur at
6 to 7-year intervals, usually in spring,
U.S. authorities are concerned about
the repetition of this problem in 19701971. Fortunately, the recent development and availability of an effective
rubella vaccine may avert this tragedy
if immunization is properly and widely
used.
The vaccine is the direct descendant
of viruses first isolated by Parkman,
and independently by Weller and their
co-workers in 1961. In the United
States, it is expected that the vaccine
will control rubella through the establishment of "herd immunity" among
children, the group in which the disease
is most common. It is the children who
usually transmit the teratogenic virus to

the 15%to 20% of pregnant women
who are susceptible. Because mass
vaccination programs have largely
eliminated polio and sharply curtailed
measles (rubeola) by the establishment
of herd immunity, it is felt the same
can be accomplished with the rubella
vaccine. To this end, the live, attenuated rubella virus vaccine should be
given to all children—boys as well as
girls—between the ages of one year
and extending through the elementary
school population.
In addition, the physician will be
requested to give the vaccine to many
adult women. The susceptibility to rubella in these patients may be demonstrated by absence of specific serum
hemagglutinating antibody. Since the
vaccine virus can infect the fetus, immunization should be used only if pregnancy can be excluded in sexuallyactive women of child-bearing age and
wiU be avoided for at least three months
after vaccination. This requires a negative pregnancy test, administration of
vaccine during a menstrual period or
immediately after childbirth. Prevention of conception must be assurred by
abstinence or use of effective contraceptives during the ensuing few months.
In children, reactions to vaccine are
rare, ie, occasional mild fever, local
soreness at the site of injection and
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arthralgia. Rash was reported in only
a few instances. Spread of the vaccine
virus to others has not been a problem.
Arthralgia and transient arthritis occur more frequently in women than in
children. Further attenuation of the
virus in the vaccine may reduce adverse reactions but may also reduce
the vaccine's protective values. When
they were adequately prewarned, patients to whom we gave the vaccine

willingly accepted the possibility and
occurrence of adverse reactions.
The use of the live rubeUa virus
vaccine should be avoided in patients
with altered immune states or hypersensitivity to vaccine components (indicated on the label). Also, present
recommendations are that administration should be separated by at least
one month from the administration of
other live virus vaccines.
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